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Abstract: Osteogenesis imperfecta (OI) is a rare inherited disorder with a broad spectrum 
of clinical and genetic variability. The genetic diversity involves, in the majority of the cases, 
mutations in one of the genes that encodes the type 1 collagen protein (COL1 A1 and COL1 A2), 
but it is not a requirement for the diagnosis. The most benign form is OI type I. The authors 
present a case report of a 25-year-old woman who had severe low back pain associated with 
incapacity to walk and breast-feed post-partum. Symptoms developed 2 weeks after delivery. 
The radiological examination revealed severe osteoporosis with no abnormalities in the labora-
tory findings. The clinical signs and a positive personal and family history of multiple fractures 
in childhood suggested OI type I, although other diagnosis, such as pregnancy-associated 
osteoporosis, was also considered. The atypical presentation of this rare disorder in adulthood 
calls attention to the need for early diagnosis for prompt treatment. Treatment of OI is never 
curative, but it improves the quality of the patient’s life.
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Introduction
Osteogenesis Imperfecta (OI), also known as the “brittle bone disease”, is a heritable 
connective tissue disorder, characterized by bone fragility due to low bone mass, with 
an increased propensity to fractures and bone deformity. It is a rare disorder with an 
incidence of up to 1/30,000 and a prevalence of 6 to 7/100,000 births.1,2
Patients with OI present small, slender bones and the fractures affect mainly the 
spine and the extremities. The most frequent extraskeletal clinical features are the eye 
(blue sclera), hyperlaxity of ligaments and skin, hearing impairment, dentinogenesis 
imperfecta, and the presence of wormian bones on skull radiographs.3,4
In recent decades there has been a tendency to view OI as an autosomal dominant 
disorder of type I collagen, a major structural protein of the extracellular matrix of 
the bone. This suggested that most of the cases would have aroused from a mutation 
in one of the two genes, which encoded the α-chains of the collagen type I (COL1 A1 
and COL1 A2 genes).5 However, in recent years, the molecular understanding of this 
disease recognized newer autosomal recessive forms of OI (types V , VI, and VII) not 
associated with type I collagen gene defects. This allowed the modification, of the 
original Sillence classification (Table 1), in a large number of subgroups, based on new 
clinical, radiological and histological features and type of mutation involved.1,3
Diagnosis of OI is straightforward in individuals with a positive family history. 
However, there are some forms of OI (such as OI type I) with mild clinical expres-
sion where other possible diagnosis, such as idiopathic juvenile osteoporosis, must International Medical Case Reports Journal 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
26
Rebelo et al
be considered. In these cases cultured skin fibroblasts and/or 
genetic analysis may be helpful in confirming the diagnosis.6,7 
Alternatively, analysis of the DNA with the screening of 
the coding region of the COL1 A1 and the COL1 A2 genes 
may identify the mutation.3,6 Genomic DNA sequencing is 
more sensitive than fibroblast cultures and allows screening 
the mutation in other family members. Both approaches are 
thought to detect 90% of the collagen type 1 mutations.3,8–10
A consistent genotype–phenotype correlation is still not 
fully defined. Therefore, it is not possible to predict with 
certainty the phenotypic effect of a particular mutation.3,4,6,11,12 
Because of the highly variable expression in OI, individuals 
with the same genotype have different phenotype, which is 
an interesting feature of many dominant disorders.12 More-
over mutations are absent or located in a different gene in 
a considerable number of individuals.4 For these reasons, 
the definition of OI should remain on signs and symptoms 
outlined above.3,4
Genetic counseling is an important component of the 
diagnostic approach, since individuals who are affected with 
dominant OI trait have a 50% risk of transmission with each 
pregnancy.
Treatment of OI involves a multidisciplinary approach. 
Physiotherapy, rehabilitation, and orthopedic surgery are the 
mainstays of treatment. In recent years there have been devel-
opments in the medical management of OI. Biphosphonates 
have been shown to increase bone turnover, decrease fracture 
rates, and relieve symptoms in patients with OI.4
The following case report calls attention to the challenging 
diagnosis of OI type I, whose clinical features may overlap the 
symptoms of other disorders. The diagnosis of the milder forms 
of OI requires a high index of suspicion, along with proper 
follow up and counseling to prevent further complications.
Case report
A previously healthy 25-year-old woman was admitted to the 
emergency department complaining of severe low back pain. 
The patient was unable to carry her 3-month-old baby and 
she was having difficulties in walking and doing her daily 
activities, because of back pain. There was tenderness in all 
Table 1 Classification of osteogenesis imperfecta (modification of the original Sillence classification:1–4)
Type Inheritance 
pattern
Clinical features Mutations usually 
associated
I  AD Normal or mild short stature; blue 
sclera; no dentinogenesis imperfecta.
Premature termination 
codons in COL1A1
II AD Multiple rib fractures at birth; 
pronounced deformities; broad long 
bones; low density skull bones; dark 
sclera. Lethal form.
Glycine substitutions in 
COL1A1 or COL1A2
III AD Very short, triangular face; severe 
scoliosis, greyish sclera; 
dentinogenesis imperfecta.
Glycine substitutions in 
COL1A1 and COL1A2
IV AD Moderately short; mild to moderate 
scoliosis; greyish or white sclera; 
dentinogenesis imperfecta.
Glycine substitutions in 
COL1A1 and COL1A2
V AD2,3 Mild to moderate short stature; 
dislocation radia head; mineralized 
interosseous membrane; hyperplastic 
callus; white sclera; no dentinogenesis 
imperfecta.
Unknown
VI AR2,4 Moderately short; scoliosis; 
accumulation of osteoid in the bone 
tissue, fish-scale pattern bone 
lamellation; white sclera; no 
dentinogenesis imperfecta.
Unknown
VII AR1,3 severe osteoporosis with rhizomelia, 
neonatal fractures, short humeri and 
femora, gracile ribs, white sclera.
Mutations in CRTAP
VIII AR1,3  Rhizomelia and severe 
undertubulation of the long bones. In 
utero fractures. Ribs with no or few 
fractures. White sclera. No 
dentinogenesis imperfecta.
Mutations in LEPRE1 
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spinous process with restricted spinal range motion and spasm 
on vertebral muscles. She denied recent trauma or intense 
exercise. Neurological examination was unremarkable. The 
low back pain began in the third trimester of pregnancy, but 
was not as debilitating as after delivery. On physical examina-
tion the patient presented a triangular-shaped face, blue sclera 
(Figure 1), and short stature. She did not have discolored teeth. 
Her height was 150 cm and weight 51 kg (before pregnancy 
her weight was around 42 kg). Both pregnancy and labor were 
carried out without any other intervention. She denied taking 
any drugs and she was a non-smoker.
A renal ultrasound did not reveal any abnormality. The 
spine X-ray and the lumbar CT-scan showed diffuse low 
bone density (Figure 2). Laboratory assessment included 
erythrocyte sedimentation rate, serum creatinine, calcium, 
phosphorus, liver enzymes (alanine aminotransferase 
[ALT], aspartate aminotransferase), thyroid hormones, 
parathyroid hormone, osteocalcin, and 25-hydroxyvita-
min D (25-OHD), and urinary excretion of calcium and 
hydroxyproline were within the normal range, except for 
an elevated ALT (260 U/L, N: 36–101). Antibodies for the 
celiac disease were negative. The protein electrophoresis 
was also in normal range. Because of the intensity of the 
symptoms and the laboratory and radiological negativ-
ity for arthritis, a bone scintigraphy was done revealing 
signs suggestive of “old” fractures in the 7th, 8th and 9th 
right ribs, and lumbar vertebras (Figure 3). Bone mineral 
density (BMD) was measured by using dual-energy X-ray 
absorptiometry (DEXA) and the results showed a total T 
score of –4.1 for the lumbar spine (L1–L4) (Table 2), which 
indicated severe bone loss (osteoporosis). Further review 
of the patient’s past medical history revealed multiple 
episodes of fractures during childhood and adolescence: 1 
tibial and 3 rib fractures. There was also a positive family 
history of premature osteoporosis in her mother and history 
of fractures in 2 aunts. These findings suggested the diagnosis 
of a mild form OI type I.
Figure 1 Blue sclera.
Figure 2 Lumbar spine X-ray (A) and computed tomography scan (B, sagittal view 
and C, axial view) of the spine showing diffuse low bone density.
Figure 3 Bone scintigraphy (A, anterior view, B, posterior view) showing increased 
uptake in the 7th, 8th and 9th right ribs (arrows).
The patient began analgesic treatment with acetamino-
phen 1 g 3 times a day and also intranasal calcitonin (200 
IU/day), alendronate (70 mg/week), elementary calcium 
(1000 mg/day), and vitamin D. A thoracolumbosacral 
orthosis (TLSO) was prescribed and she was advised to 
bottle-feed her baby. After 6 months’ treatment her symp-
toms improved. Low back pain disappeared completely International Medical Case Reports Journal 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
28
Rebelo et al
and she was able to walk and carry her baby. The TLSO 
was then discontinued. After 1-year follow-up she denied 
back pain and was able to carry out her daily activities 
at work and at home. Three years after starting treatment 
with oral alendronate, the lumbar spine BMD increased by 
31.6% (Table 2). Recently, alendronate was substituted by 
strontium ranelate and she is currently on antiosteoporotic 
treatment.
The patient’s son was sent to a metabolic and genetic 
diseases outpatient clinic of the pediatric hospital. When 
he was 1 year old he had a fracture of the 7th rib after a 
minor trauma. Laboratory workup excluded metabolic and 
endocrine abnormalities. Based on clinical findings (blue 
sclera and fractures) and positive family history, he was also 
diagnosed with OI. He was treated with pamidronate given in 
cycles of 3 days, repeated every 2 months for 9 months, and 
since then he has had no other episode of fractures.
Discussion
OI type I is the most prevalent form of OI and is often undi-
agnosed during childhood because children rarely develop 
significant physical deformities. It is caused by quantitative 
defects in collagen production, although the collagen pro-
duced is structurally normal. Patients typically have blue 
sclera, short stature and a triangular face shape. They tend 
to present early osteoporosis. Dentinogenesis imperfecta is 
uncommon, but hearing impairment is possible (Table 1).
The present patient had been experiencing low back pain 
that, during pregnancy, was attributed to a mechanical condi-
tion. This resulted in increasing pain and inability to perform 
her daily activities and breast-feeding after pregnancy. At 
physical examination the patient presented blue sclera, a tri-
angular-shaped face, short stature, but no physical deformity 
and no dentinogenesis imperfecta. Radiological findings were 
suggestive of osteoporosis. Clinical history and laboratory 
assessment excluded metabolic, endocrine (ie, hyperparathy-
roidism), and infectious causes for her symptoms. There were 
no eating disorders and she was not overweight.
Although clinical features were in favor of a diagnosis of 
a mild form of OI, pregnancy-associated osteoporosis (PAO) 
was also considered in the differential diagnosis.
PAO is a rare and transient form of osteoporosis. Its 
incidence is underestimated, since back pain in a pregnant 
or lactating woman is normally attributed to mechanical 
conditions. Patients complain of low back, ankle and hip pain 
developing in the last trimester or after delivery, and these 
conditions are often interpreted as normal for pregnancy.13,14 
If the disease is recognized early and treated, the prognosis is 
good for subsequent pregnancies. The risk of fracture recur-
rence is low even in the absence of pregnancy, but not negli-
gible.15 The PAO is characterized as a localized osteoporosis 
of unknown etiology in contrast to the diffuse generalized 
osteoporosis of the post-menopausal women.
In the presenting case we could not exclude the existence 
of genetic predisposition, since the patient’s mother and aunt 
suffered from early osteoporosis with a past medical history 
of multiple fractures. However, genetic analysis of COL1 A1 
could not be done. Scintigraphy revealed the existence of 
old fractures and DEXA results confirmed the existence of 
severe osteoporosis. These findings, in conjunction, with the 
clinical features and a positive personal and family history, 
supported the diagnosis of OI type I.
Analgesic treatment with acetaminophen and intranasal 
calcitonin allowed fast pain relief. Antiresorptive agents such 
as biphosphonates are considered the first-line treatment for 
osteoporosis. In this case, because of severe osteoporosis, 
the patient was treated with oral alendronate, calcium, and 
vitamin D. Breastfeeding was stopped because of the negative 
effect on BMD and calcium metabolism.5 After 6 months’ 
treatment, symptoms improved and after a 3-year-treatment 
with alendronate, there was an increase in bone mass density 
(Table 2). The recent substitution of oral alendronate for 
strontium ranelate was based on scientific evidence that sup-
port its efficacy for BMD and improvements in bone cortical 
microarchitecture that decrease fracture rate in osteoporotic 
women,16 and because current studies have demonstrated 
Table 2 Dual-energy X-ray absorptiometry results revealing an increase of bone mineral density (BMD) of the lumbar spine in the 
3 years after treatment with alendronate
Region: 2007 2010
BMD (g/cm2) T score Z Score BMD (g/cm2) T score Z score
L1 0.427 -4.5 -4.5 0.616 -2.1 -2.0
L2 0.580 -4.1 -4.0 0.476 -2.2 -2.2
L3 0.692 -3.6 -3.5 0.858 -1.6 -1.5
L4 0.657 -4.2 -4.1 0.715 -1.9 -1.8
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the long-term use of biphosphonates is associated with an 
increased risk of uncommon side-effects, such as osteone-
crosis of the jaw and atypical fractures.17
Surgical interventions, which are alternative treatment 
options for OI when medical therapy fails, were not necessary 
since there was a good response to medical treatment. No 
other fractures have occurred. In OI type I there is a 50% risk 
of transmitting the disease and in the presenting case it was 
also diagnosed on our patient’s son.2 He was also treated with 
biphosphonates. There have been some concerns about the use 
of bisphosphonates in children, because of possible interfer-
ence with the rapid remodeling process, which is necessary 
in growing bones, and which can result in bone deformity 
or serious disruption of the normal mineralization process. 
However, to date, studies have shown that the linear growth of 
children on biphosphonate treatment is not affected.5,18
This case presentation illustrates the importance of early 
recognition of the different possible factors for a low back 
pain in young pregnant women. OI should always be kept in 
mind as a possible cause.
Conclusion
OI is a rare disorder that should always be kept in mind as 
possible cause of chronic low back pain and osteoporosis in 
a pregnant or lactating woman. In our case report the clinical 
features and positive personal and family history were very 
suggestive of OI type I. Because of subtle clinical features 
this disorder may remain undiagnosed until adulthood. OI is 
associated with bone fragility and increased risk for fractures, 
and therefore prompt medical management is mandatory. 
Biphosphonates are the cornerstone therapy and the response 
to treatment is measured with BMD.
The goal in OI type I patients is to promote general physi-
cal well-being, reduce the risk of fracture, and increase bone 
density. Medical treatment is not curative, but it improves 
the patient’s quality of life.
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